Elderly patients with Lung Cancer
Real world patients diagnosed with lung cancer are aged on the one hand (median age around 70 years) and often frail on the other. In the past years the treatment landscape of NSCLC has changed drastically with the introduction of novel targeted agents, immunotherapy and several different combination regimens. However, in most trials’ patients are young (often median 60-65 years of age) and fit (ECOG 0-1, no comorbidities).
Management of elderly patients with NSCLC
Non-small-cell lung cancer (NSCLC) is a very common disease in the elderly population and its incidence in this particular population is expected to increase further, because of the ageing of the Western population. Despite this, limited data are available for the treatment of these patients and, therefore, the development of evidence-based treatment recommendations is challenging.